ATE339197T1 - 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3- 4-pyrimindin-3-yl)pyrimidin-2-yl-amino)phenyl)- benzamide zur behandlung von ang-ii vermittelt krankheiten - Google Patents

4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3- 4-pyrimindin-3-yl)pyrimidin-2-yl-amino)phenyl)- benzamide zur behandlung von ang-ii vermittelt krankheiten

Info

Publication number: ATE339197T1
Authority: AT; Austria
Prior art keywords: methyl; treatment; benzamide; ylmethyl; pyrimidine
Prior art date: 2002-03-15

Application number

AT03727265T

Other languages

English (en)

Inventor

Richard Ernest Gilbert

Darren James Kelly

David Louis Feldman

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-15

Filing date

2003-03-14

Publication date

2006-10-15

2002-03-15 Priority claimed from GB0206217A external-priority patent/GB0206217D0/en

2002-03-15 Priority claimed from GB0206216A external-priority patent/GB0206216D0/en

2002-07-29 Priority claimed from GB0217505A external-priority patent/GB0217505D0/en

2003-03-14 Application filed by Novartis Ag filed Critical Novartis Ag

2006-10-15 Application granted granted Critical

2006-10-15 Publication of ATE339197T1 publication Critical patent/ATE339197T1/de

Links

201000010099 disease Diseases 0.000 title abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 title 1
230000001404 mediated effect Effects 0.000 title 1
206010020772 Hypertension Diseases 0.000 abstract 2
108010055723 PDGF receptor tyrosine kinase Proteins 0.000 abstract 2
229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 abstract 2
229940123338 Aldosterone synthase inhibitor Drugs 0.000 abstract 1
102000005862 Angiotensin II Human genes 0.000 abstract 1
101800000733 Angiotensin-2 Proteins 0.000 abstract 1
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 abstract 1
229940083712 aldosterone antagonist Drugs 0.000 abstract 1
239000002170 aldosterone antagonist Substances 0.000 abstract 1
229950006323 angiotensin ii Drugs 0.000 abstract 1
229940125364 angiotensin receptor blocker Drugs 0.000 abstract 1
230000003276 anti-hypertensive effect Effects 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

AT03727265T 2002-03-15 2003-03-14 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3- 4-pyrimindin-3-yl)pyrimidin-2-yl-amino)phenyl)- benzamide zur behandlung von ang-ii vermittelt krankheiten ATE339197T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0206217A GB0206217D0 (en)	2002-03-15	2002-03-15	Organic compounds
GB0206216A GB0206216D0 (en)	2002-03-15	2002-03-15	Organic compounds
GB0217505A GB0217505D0 (en)	2002-07-29	2002-07-29	Organic compounds

Publications (1)

Publication Number	Publication Date
ATE339197T1 true ATE339197T1 (de)	2006-10-15

Family

ID=28045959

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03727265T ATE339197T1 (de)	2002-03-15	2003-03-14	4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3- 4-pyrimindin-3-yl)pyrimidin-2-yl-amino)phenyl)- benzamide zur behandlung von ang-ii vermittelt krankheiten

Country Status (11)

Country	Link
US (1)	US20050124624A1 (de)
EP (1)	EP1487424B1 (de)
JP (1)	JP2005527523A (de)
AT (1)	ATE339197T1 (de)
AU (1)	AU2003233946A1 (de)
CY (1)	CY1105839T1 (de)
DE (1)	DE60308337T2 (de)
DK (1)	DK1487424T3 (de)
ES (1)	ES2274234T3 (de)
PT (1)	PT1487424E (de)
WO (1)	WO2003077892A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004037261A1 (en) *	2002-10-25	2004-05-06	The Administrators Of The Tulane Educational Fund	Use of n-‘5-‘4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension
US20050267182A1 (en)	2003-11-13	2005-12-01	Ambit Biosciences Corporation	Urea derivatives as FLT-3 modulators
CN1917865A (zh) *	2004-01-22	2007-02-21	诺瓦提斯公司	有机化合物的组合
GB0401761D0 (en) *	2004-01-27	2004-03-03	Novartis Ag	Organic compounds
MY144177A (en)	2004-02-04	2011-08-15	Novartis Ag	Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide.
MY148074A (en) *	2005-05-10	2013-02-28	Novartis Ag	Pharmaceutical compositions comprising imatinib and a release retardant
EP1741432A1 (de) *	2005-07-07	2007-01-10	Universitätsklinikum Freiburg	Tyrosinkinase-Inhibitor Imatinib zur Behandlung von Bluthochdruck
DE102005042544A1 (de) *	2005-09-07	2007-03-08	Ernst-Moritz-Arndt-Universität	Beeinflussung des kardialen Fc-Rezeptors zur Behandlung der dilatativen Kardiomyopathie
US20090304625A1 (en) *	2006-01-18	2009-12-10	Ahsan Husain	Modulators of cardiac cell hypertrophy and hyperplasia
NZ570943A (en) *	2006-03-13	2010-09-30	Encysive Pharmaceuticals Inc	Polymorphs of sitaxsentan
AU2007225139A1 (en) *	2006-03-13	2007-09-20	Encysive Pharmaceuticals, Inc.	Methods and compositions for treatment of diastolic heart failure
BRPI0715634A2 (pt) *	2006-09-01	2013-07-02	Teva Pharma	composiÇÕes de imatinibe
TW201006823A (en) *	2008-07-14	2010-02-16	Novartis Ag	Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
EP3942045A1 (de)	2019-03-21	2022-01-26	Onxeo	Dbait-molekül in kombination mit einem kinaseinhibitor zur behandlung von krebs
US12523663B2 (en)	2019-06-04	2026-01-13	Inserm (Institut National De La Santé Et De La Rescherche Médicale)	Use of CD9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
EP4054579A1 (de)	2019-11-08	2022-09-14	Institut National de la Santé et de la Recherche Médicale (INSERM)	Verfahren zur behandlung von krebsarten, die resistenz gegen kinase-inhibitoren erworben haben
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
CN121712504A (zh) *	2023-07-27	2026-03-20	矿物疗法公司	用洛伦司他及两种或更多种降压药的组合治疗高血压的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5521184A (en) *	1992-04-03	1996-05-28	Ciba-Geigy Corporation	Pyrimidine derivatives and processes for the preparation thereof
US20010051631A1 (en) *	1994-07-15	2001-12-13	Muneo Takatani	Tricyclic compounds, their production and use
ES2167571T3 (es) *	1995-06-07	2002-05-16	Searle & Co	Terapia de combinacion de antagonista de aldosterona epoxi-esteroideo y antagonista de angiotensina ii para el tratamiento del fallo cardiaco congestivo.
CO4940418A1 (es) *	1997-07-18	2000-07-24	Novartis Ag	Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso

2003
- 2003-03-14 US US10/507,642 patent/US20050124624A1/en not_active Abandoned
- 2003-03-14 EP EP03727265A patent/EP1487424B1/de not_active Expired - Lifetime
- 2003-03-14 AU AU2003233946A patent/AU2003233946A1/en not_active Abandoned
- 2003-03-14 AT AT03727265T patent/ATE339197T1/de active
- 2003-03-14 WO PCT/EP2003/002709 patent/WO2003077892A2/en not_active Ceased
- 2003-03-14 DK DK03727265T patent/DK1487424T3/da active
- 2003-03-14 JP JP2003575945A patent/JP2005527523A/ja active Pending
- 2003-03-14 PT PT03727265T patent/PT1487424E/pt unknown
- 2003-03-14 DE DE60308337T patent/DE60308337T2/de not_active Expired - Lifetime
- 2003-03-14 ES ES03727265T patent/ES2274234T3/es not_active Expired - Lifetime
2006
- 2006-12-11 CY CY20061101774T patent/CY1105839T1/el unknown

Also Published As

Publication number	Publication date
DE60308337T2 (de)	2007-09-20
AU2003233946A1 (en)	2003-09-29
ES2274234T3 (es)	2007-05-16
JP2005527523A (ja)	2005-09-15
PT1487424E (pt)	2007-01-31
CY1105839T1 (el)	2011-04-06
DK1487424T3 (da)	2007-01-08
US20050124624A1 (en)	2005-06-09
EP1487424A2 (de)	2004-12-22
DE60308337D1 (de)	2006-10-26
WO2003077892A3 (en)	2003-12-24
EP1487424B1 (de)	2006-09-13
AU2003233946A8 (en)	2003-09-29
WO2003077892A2 (en)	2003-09-25

Legal Events

Date

Code

Title

Description

2007-03-15

UEP

Publication of translation of european patent specification

Ref document number: 1487424

Country of ref document: EP

Publication	Publication Date	Title
DE60308337D1 (de)	2006-10-26	4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3-(4-pyrimindin-3-yl)pyrimidin-2-yl-amino)phenyl)-benzamide zur behandlung von ang-ii vermittelt krankheiten
ATE521354T1 (de)	2011-09-15	Kombination aus imatinib und einem histondeacetylase-hemmer zur behandlung von leukämie
DE60118430D1 (de)	2006-05-18	Behandlung gastrointestinaler stroma-tumoren
NO20034713D0 (no)	2003-10-21	Kombinasjon omfattende N-{5-[4-(4-metylpiperazinometyl)- benzoylamido]-2-metylfenyl}-4-(3-pyridyl)-2-pyrimidinamin og et kjemoterapeutiskmiddel
AR053984A1 (es)	2007-05-30	Combinacion de un inhibidor de proteina cinasa src y un inhibidor bcr - abl para el tratamiento de enfermedades proliferativas
BR0207649A (pt)	2004-03-09	Combinação compreendendo um inibidor de transdução de sinal e um derivado de epotilona
AU2003272007A1 (en)	2004-05-13	Use of n-5-4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension
IL176070A0 (en)	2006-10-05	COMBINATION OF (a) N-{5-[4-(4-METHYL-PIPERAZINO-METHYL)-BENZOYLAMIDO]-2-METHYLPHENYL}-4-(3-PYRIDYL)-2-PYRIMIDINE-AMINE AND (b) AT LEAST ONE HYPUSINATION INHIBITOR AND THE USE THEREOF
ATE468855T1 (de)	2010-06-15	Kombination von stickstoff-senf analogen und imatinib für die behandlung von chronischer lymphatischer leukämie
DE60319211D1 (de)	2008-04-03	Kombination von glivec (sti571) mit einem cyclinabhängigen kinaseinhibitoren, ins besonders flavopiridol, zur behandlung von krebs
DK1631291T3 (da)	2009-11-02	Anvendelse af tyrosinkinaseinhibitorer til behandling af diabetes
ATE476183T1 (de)	2010-08-15	Verfahren zur behandlung von soliden tumoren einschliesslich der verabreichung einer kombination mit imatinib und einem effluxpumpenhemmer
AU2003209521A1 (en)	2003-09-09	Use of 4-(4-methylpiperazin-1-ylmethyl)-n(4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl)-benzamide for treating seminomas
SI1487424T1 (sl)	2007-04-30	4-(4-metilpiperazin-1-ilmetil)-N-(4-metil-3(4-piridin-3-il)pirimidin-2- il-amino)fenil)-benzamid za zdravljenje bolezni, posredovanih preko ang II